The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
Open accessAbstract
INTRODUCTION: Information detailing the experience of patients with light chain (AL) amyloidosis is lacking. The primary aim of this study was to gather data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care. METHODS: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). Participants with AL amyloidosis were sent an eight-question follow-up survey. RESULTS: The initial survey was completed by 533 participants (follow-up survey completed by 201 participants). AL amyloidosis was the most common diagnosis. For 37.1% of respondents, the diagnosis of amyloidosis was not established until ≥ 1 year after the onset of initial symptoms. Diagnosis was received after visits to 1, 2, 3, 4, or ≥ 5 physicians by 7.6%, 23.5%, 20.3%, 16.8%, and 31.8% of respondents, respectively. Correct diagnosis was most often made by hematologists/oncologists (34.1%). Treatments included chemotherapy (63.1%) and stem cell transplantation (38.9%) and were difficult to tolerate for 54.1% of respondents. A significant number of respondents felt uninformed about clinical trials. Nevertheless, approximately half (46.1%) believed that enrolling in a trial would enhance their care. CONCLUSIONS: Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improved, especially given that respondents indicated high willingness to participate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationGertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Comenzo, R. L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V, Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.100 · Cited by 390
Self-citationImmunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Gertz, M. A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23828 · Cited by 245
Systemic light chain amyloidosis: an update for treating physicians
Merlini, G., Wechalekar, A. D., & Palladini, G. (2013) · Blood · doi:10.1182/blood-2013-01-453001 · Cited by 235
Self-citationLight-Chain (AL) Amyloidosis: Diagnosis and Treatment
Sanchorawala, V. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02740806 · Cited by 214
Guidelines on the management of AL amyloidosis
Wechalekar, A. D., Gillmore, J. D., Bird, J. M., Cavenagh, J. D., Hawkins, S., Kazmi, M. A., Lachmann, H. J., Hawkins, P. N., & Pratt, G. (2014) · British Journal of Haematology · doi:10.1111/bjh.13155 · Cited by 128
Immunoglobulin light chain amyloidosis
Merlini, G., Comenzo, R. L., Seldin, D. C., Wechalekar, A. D., & Gertz, M. A. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2014.858594 · Cited by 110
Self-citationAmyloidosis: Diagnosis and Treatment
Gurevitz, S. A., & Stone, M. J. (2012) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2012.11928822 · Cited by 73
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationAddressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citationSystemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Gertz, M. A., & Dispenzieri, A. (2020) · JAMA · doi:10.1001/jama.2020.5493 · Cited by 366
Metadata
- Authors
- Lousada, I., Comenzo, R. L., Landau, H., Guthrie, S., & Merlini, G.
- Venue
- Advances in Therapy
- Published
- 2015-10
- Volume
- 32
- Issue
- 10
- Pages
- 920-928
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2115902267
- Cited by
- 269
- References
- 10
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. https://app.cochat.ai/papers/10.1007/s12325-015-0250-0
- The paper
- Lousada, I., Comenzo, R. L., Landau, H., Guthrie, S., & Merlini, G. (2015). Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Advances in Therapy. https://doi.org/10.1007/s12325-015-0250-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.